October 15, 2019
Aura Biosciences candidate AU-011 could be first FDA approved therapy for primary treatment chorodial melanoma
Aura Biosciences said in a presentation at American Academy od Ophtalmology that its lead product candidate light-activated AU-011 has the potential to be the first FDA approved therapy for the primary treatment of choroidal melanoma.